[go: up one dir, main page]

PE20160050A1 - INHIBITORS / ANTIANDROGENS NOVEL CYP17 - Google Patents

INHIBITORS / ANTIANDROGENS NOVEL CYP17

Info

Publication number
PE20160050A1
PE20160050A1 PE2015002562A PE2015002562A PE20160050A1 PE 20160050 A1 PE20160050 A1 PE 20160050A1 PE 2015002562 A PE2015002562 A PE 2015002562A PE 2015002562 A PE2015002562 A PE 2015002562A PE 20160050 A1 PE20160050 A1 PE 20160050A1
Authority
PE
Peru
Prior art keywords
alkyl
inhibitors
halogen
compounds
antiandrogens
Prior art date
Application number
PE2015002562A
Other languages
Spanish (es)
Inventor
Anssi Haikarainen
Arja Karjalainen
Mikko Passiniemi
Gerd Wohlfahrt
Petteri Rummakko
Eija Tiainen
Emilia Vaisanen
Pekka Pietikainen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of PE20160050A1 publication Critical patent/PE20160050A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE Z1 Y Z2 SON CADA UNO C O N; A ES UN ANILLO CARBOCICLICO DE 3-7 MIEMBROS NO AROMATICO, ENTRE OTROS; B ES UN ANILLO HETEROCICLICO DE 5-6 MIEMBROS, ENTRE OTROS; R1 ES HALOGENO, CF3, ENTRE OTROS; R2 ES CN O NITRO; R3 ES H, HALOGENO O ALQUILO C1-C7; R4 ES ALQUILO C1-C7, ENTRE OTROS; R5 ES H, OH, ENTRE OTROS; R5', R6' Y R6 SON CADA UNO H, OH, ALQUILO C1-C7 O HALOGENO; R7 ES H, OH, CN, ENTRE OTROS; R8 ES H O ALQUILO C1-C7. SON COMPUESTOS PREFERIDOS: 4-(ETIL(3-(2-METIL-2H-TETRAZOL-5-IL)CICLOHEXIL)AMINO)-2-(TRIFLUOROMETIL)BENZONITRILO; 4-((3-(1H-IMIDAZOL-1-IL)-6,6-DIMETILCICLOHEX-2-EN-1-IL)(ETIL)AMINO)-2-(TRIFLUOROMETIL)BENZONITRILO; ENTRE OTROS. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE ANDROGENOS E INHIBIDORES DEL CITOCROMO MONOOXIGENASA P450 17ALFA-HIDROXILASA/17,20-LIASA (CYP17) SIENDO UTILES PARA EL TRATAMIENTO DE CANCER DE PROSTATAREFERS TO HETEROCICLIC COMPOUNDS OF FORMULA (I) WHERE Z1 AND Z2 ARE EACH C O N; A IS A CARBOCYCLIC RING OF 3-7 NON-AROMATIC MEMBERS, AMONG OTHERS; B IS A HETEROCYCLIC RING OF 5-6 MEMBERS, AMONG OTHERS; R1 IS HALOGEN, CF3, AMONG OTHERS; R2 IS CN OR NITRO; R3 IS H, HALOGEN, OR C1-C7 ALKYL; R4 IS C1-C7 ALKYL, AMONG OTHERS; R5 IS H, OH, AMONG OTHERS; R5 ', R6' AND R6 ARE EACH H, OH, C1-C7 ALKYL OR HALOGEN; R7 IS H, OH, CN, AMONG OTHERS; R8 IS H OR C1-C7 ALKYL. PREFERRED COMPOUNDS ARE: 4- (ETHYL (3- (2-METHYL-2H-TETRAZOL-5-IL) CYCLOHEXYL) AMINO) -2- (TRIFLUOROMETHYL) BENZONITRILE; 4 - ((3- (1H-IMIDAZOL-1-IL) -6,6-DIMETHYL CYCLOHEX-2-EN-1-IL) (ETHYL) AMINO) -2- (TRIFLUOROMETHYL) BENZONITRILE; AMONG OTHERS. SUCH COMPOUNDS ARE ANDROGEN RECEPTOR ANTAGONISTS AND INHIBITORS OF CYTOCHROME MONOOXIGENASE P450 17ALFA-HYDROXYLASE / 17,20-LIASA (CYP17), BEING USEFUL FOR THE TREATMENT OF PROSTATE CANCER

PE2015002562A 2013-06-11 2014-06-10 INHIBITORS / ANTIANDROGENS NOVEL CYP17 PE20160050A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361833846P 2013-06-11 2013-06-11

Publications (1)

Publication Number Publication Date
PE20160050A1 true PE20160050A1 (en) 2016-02-18

Family

ID=51062835

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002562A PE20160050A1 (en) 2013-06-11 2014-06-10 INHIBITORS / ANTIANDROGENS NOVEL CYP17

Country Status (21)

Country Link
US (1) US9890139B2 (en)
EP (1) EP3008042A1 (en)
JP (1) JP6356790B2 (en)
KR (1) KR20160019928A (en)
CN (1) CN105339355B (en)
AR (1) AR101051A1 (en)
AU (1) AU2014283150B2 (en)
CA (1) CA2912166A1 (en)
CL (1) CL2015003595A1 (en)
EA (1) EA029280B1 (en)
HK (1) HK1220690A1 (en)
MA (1) MA38645B1 (en)
MX (1) MX2015016943A (en)
PE (1) PE20160050A1 (en)
PH (1) PH12015502723A1 (en)
SA (1) SA515370266B1 (en)
SG (1) SG11201509449XA (en)
TW (1) TW201534586A (en)
UA (1) UA116808C2 (en)
WO (1) WO2014202827A1 (en)
ZA (1) ZA201508398B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1247204A1 (en) * 2015-01-20 2018-09-21 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of the androgen receptor
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
AR110412A1 (en) 2016-12-22 2019-03-27 Orion Corp CYP11A1 INHIBITORS
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
TWI692679B (en) * 2017-12-22 2020-05-01 美商慧盛材料美國責任有限公司 Photoresist stripper
CN108586443B (en) * 2018-01-31 2019-11-26 佳木斯大学附属第一医院 A kind of drug and preparation method thereof for preventing and treating lung bronchogenic carcinoma
CN114235972B (en) * 2021-10-28 2023-08-22 乳源东阳光药业有限公司 Method for determining content of linagliptin impurity RBP-1
WO2023091726A1 (en) * 2021-11-18 2023-05-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin‑dependent kinase 12 (cdk12)
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114369030B (en) * 2022-01-14 2024-10-01 浙江大学衢州研究院 Preparation method of 2, 4-tetramethyl-1, 3-cyclobutanediamine
AU2024270498A1 (en) * 2023-05-11 2025-11-27 Foshan Ionova Biotherapeutics Co., Inc. Novel compounds as cyp11a1 inhibitors and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546194A (en) 1984-05-29 1985-10-08 G. D. Searle & Co. Substituted chromanon-2-yl alkanols and derivatives thereof
DE3879024T2 (en) 1987-07-31 1993-10-07 Takeda Chemical Industries Ltd Pyridinium derivatives, their production and use.
ATE282623T1 (en) 1999-12-22 2004-12-15 Lilly Co Eli METHODS AND COMPOUNDS FOR INHIBITION OF MRP1
JP4272338B2 (en) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト Pyridine derivatives
JPWO2003082808A1 (en) * 2002-04-03 2005-08-04 住友製薬株式会社 Benzamide derivatives
US20060148893A1 (en) 2003-06-10 2006-07-06 Blanc Jean-Baptiste E Chemical compounds
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
WO2005108351A1 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Benzonitrile derivatives to treat musculoskeletal frailty
JP2008515998A (en) 2004-10-13 2008-05-15 スミスクライン ビーチャム コーポレーション Compound
PL1836211T3 (en) 2004-12-21 2010-07-30 Pfizer Prod Inc Macrolides
BRPI0608910A2 (en) 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc use of a compound of the formula or a pharmaceutically acceptable salt or hydrate thereof, compound or salt or hydrate thereof, pharmaceutical composition and packaged pharmaceutical composition
US20090170907A1 (en) 2005-06-06 2009-07-02 Smithkline Beecham Corporation Chemical Compounds
WO2007065093A2 (en) * 2005-11-30 2007-06-07 Smithkline Beecham Corporation Pyrrolidineanilines
US7655683B2 (en) * 2006-02-10 2010-02-02 Janssen Pharmaceutica Nv Imidazolopyrazole derivatives useful as selective androgen receptor modulators
WO2007099385A1 (en) 2006-03-01 2007-09-07 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase iv inhibitor compounds and compositions
WO2008021796A2 (en) * 2006-08-09 2008-02-21 Smithkline Beecham Corporation Pyrrolidinone anilines as progesterone receptor modulators
EP2094269A1 (en) 2006-12-19 2009-09-02 Smithkline Beecham Corporation Pyrrolidinanilines
WO2008086131A1 (en) 2007-01-12 2008-07-17 Allergan, Inc. Naphthylmethylimidizoles as therapeutic agents
WO2009124882A1 (en) 2008-04-09 2009-10-15 H. Lundbeck A/S Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists
WO2009131196A1 (en) * 2008-04-24 2009-10-29 武田薬品工業株式会社 Substituted pyrrolidine derivative and use thereof
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
SG176105A1 (en) * 2009-06-26 2011-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
CN102834380B (en) 2010-03-10 2015-04-01 阿斯利康公司 Inhibitors of protein kinases
EP2598481B1 (en) 2010-07-26 2016-08-31 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
CN102372717B (en) * 2010-08-20 2014-06-18 和记黄埔医药（上海）有限公司 Pyrrolopyrimidine compound and use thereof
JP5749341B2 (en) 2010-08-20 2015-07-15 ハチソン メディファーマ リミテッド Pyrrolopyrimidine compounds and uses thereof
WO2012125886A1 (en) 2011-03-17 2012-09-20 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
AR088082A1 (en) * 2011-10-13 2014-05-07 Lilly Co Eli ANDROGEN RECEIVER SELECTIVE MODULATORS
JP6233855B2 (en) * 2012-08-08 2017-11-22 ノバルティス・ティーアゲズントハイト・アクチェンゲゼルシャフトＮｏｖａｒｔｉｓ Ｔｉｅｒｇｅｓｕｎｄｈｅｉｔ Ａｇ Substituted azines as insecticides

Also Published As

Publication number Publication date
EP3008042A1 (en) 2016-04-20
MX2015016943A (en) 2016-04-25
PH12015502723B1 (en) 2016-03-14
MA38645B1 (en) 2018-11-30
WO2014202827A1 (en) 2014-12-24
TW201534586A (en) 2015-09-16
CA2912166A1 (en) 2014-12-24
AU2014283150B2 (en) 2018-05-10
CN105339355A (en) 2016-02-17
UA116808C2 (en) 2018-05-10
HK1220690A1 (en) 2017-05-12
KR20160019928A (en) 2016-02-22
EA201592294A1 (en) 2016-05-31
MA38645A1 (en) 2018-05-31
US9890139B2 (en) 2018-02-13
CN105339355B (en) 2018-02-27
AU2014283150A1 (en) 2015-12-03
PH12015502723A1 (en) 2016-03-14
US20160130254A1 (en) 2016-05-12
EA029280B1 (en) 2018-03-30
ZA201508398B (en) 2017-06-28
AR101051A1 (en) 2016-11-23
JP2016523851A (en) 2016-08-12
JP6356790B2 (en) 2018-07-11
SG11201509449XA (en) 2015-12-30
CL2015003595A1 (en) 2016-07-08
SA515370266B1 (en) 2018-04-15

Similar Documents

Publication Publication Date Title
PE20160050A1 (en) INHIBITORS / ANTIANDROGENS NOVEL CYP17
PE20150778A1 (en) ROR-GAMMA-T METHYLENE-LINKED QUINOLINYL MODULATORS
PE20170268A1 (en) HETEROARYL COMPOUNDS FOR KINASE INHIBITION
PE20170677A1 (en) NEW COMPOUNDS AS REORGANIZED INHIBITORS DURING TRANSFECTION (RET)
PE20160524A1 (en) THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
PE20151538A1 (en) NEW COMPOUNDS AS REORGANIZED INHIBITORS DURING TRANSFECTION (RET)
MX387984B (en) EGFR INHIBITOR AND ITS PREPARATION AND APPLICATION.
MX368066B (en) Substituted quinazolin-4-one derivatives.
PE20170774A1 (en) INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE OF THEM
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
CY1119361T1 (en) 3,4-Dihydroisoquinoline-2 (1H) -Material Compounds
PE20161073A1 (en) AMINO-HETEROARYL-BENZAMIDES AS KINASE INHIBITORS
EA201690629A1 (en) COMPOUNDS THAT ARE REPRESENTED BY TRIPLE AGONISTS, GLUCAGON, GLP-1 AND GIP
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
PE20121050A1 (en) N- (1- (4- (1H-PYRAZOLE-5-IL) FTALAZIN-1-IL) PIPERIDIN-4-IL) -BENZAMIDE COMPOUNDS SUBSTITUTE AS ANTAGONISTS IN THE HEDGEHOG TRAJECTORY
PE20161236A1 (en) TRIAZINE COMPOUND AND ITS USE FOR MEDICAL PURPOSES
MX2014002208A (en) Serine/threonine pak1 inhibitors.
EA201400338A1 (en) DERIVATIVES OF AMINOPYRIMIDINE FOR USING AS KINASE ACTIVITY MODULATORS
PE20141598A1 (en) DERIVATIVES OF DIHYDRO-BENZO-OXAZINE AND DIHYDRO-PYRID-OXAZINE
TW201613895A (en) Phosphatidylinositol 3-kinase inhibitors
EA201792374A1 (en) AZABENZIMIDAZOLES AND THEIR APPLICATION AS AMPA RECEPTOR MODULATORS
BR112018001017A2 (en) colony-stimulating factor-1 receptor (csf-1r) inhibitors
MX388321B (en) SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT WITH THEM.
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
EA202091120A3 (en) 2,4-THIAZOLINIDONE DERIVATIVES IN TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM